(COLATE) trial [8] indicated that the use of lamivudine in a salvage regimen after virological failure of a lamivudine-containing combination did not provide greater virological benefit than a salvage regimen without lamivudine when the aim is for complete viral suppression is aimed. We demonstrated that 48% of patients for whom an initial regimen of stavudine, lamivudine, and nevirapine failed would have limited options for second-line therapy using the drugs that are available in Thailand; this number increased to 63% among patients with late detection of treatment failure, and decreased to 30% among patients with early detection of treatment failure. To preserve future options for the second-line regimen in patients who experience treatment failure with a stavudine, lamivudine, and nevirapine regimen, the HIV-1 RNA assay is an important tool. This tool, as well as antiretroviral therapy, must be made more accessible in resource-limited environments. In recent years, there has been increasing concern with regard to QT interval prolongation in HIV-infected patients. Indeed, an increased prevalence of QT interval prolongation and a longer QT interval have been described in HIV-infected patients, compared with HIV-uninfected subjects [3] [4] [5] . QT interval prolongation in HIV-positive patients has been associated with alterations in cardiac innervation as a result of autonomic neuropathy [4, 6] . Moreover, several drugs administered to HIV-infected patients can cause a prolongation of the QT interval, including pentamidine [7] , pyrimethamine [8] , trimethroprim-sulfamethoxazole [9] , methadone [10] , clarithromycin [11] , and ciprofloxacin [12, 13] . Furthermore, among antiretroviral drugs, efavirenz [14] and protease inhibitors [15, 16] have been reported as potential QT interval prolongers.
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In a recent case-control study conducted at our institute, we were able to demonstrate an association between the administration of efavirenz or nelfinavir and the development of QT interval prolongation in HIV-infected individuals [17] . Moreover, we provided evidence that the risk of QT prolongation increased when efavirenz or nelfinavir therapy was combined with zidovudine therapy. In our opinion, clinicians who care for HIV-infected persons should be aware of the risk of QT interval prolongation, particularly when antiretroviral therapy is combined with drugs with known potential to prolong the QT interval.
Reply to Chinello and Petrosillo
The interest and comments expressed by Chinello and Petrosillo [1] regarding our recent article about antimicrobial-associated QT interval prolongation are greatly appreciated. Because of space constraints, we omitted any discussion regarding antivirals in our article [2] . We would like to echo the concerns raised in the letter by Chinello and Petrosillo [1] , chief among them to emphasize the awareness of QT and metabolic liability of antiretroviral therapy among practicing clinicians involved in the care of HIV-infected patients [3] . Chinello and Petrosillo [1] mention that there is a high magnitude of patients receiving antiretroviral drugs, some of which have QT liability and/or metabolic liability (table 1); HIV infection may predispose patients to QT interval prolongation; and finally, a plethora of drugs are now identified to carry QT liability, many of which are likely to be administered to patients with HIV.
What makes the aforementioned findings clinically important is the fact that these drugs collide to create "multiple hits" to an individual's repolarization reserve, potentially delaying ventricular repolarization, and if this occurs in great enough magnitude, the patient becomes susceptible to torsades de pointes. "Therapeutic complexity" is a term that defines the treatment of HIV infection today. A recent study reported that HIV-infected patients received a mean (‫ע‬SD) of concurrent medications (the 15.7 ‫ע‬ 7.7 peak end of the range was 39 drugs) [4] . Although combination therapy constitutes the backbone of an effective antiretroviral therapy regimen, the challenge becomes making polypharmaceutical treatment of HIV-infected patients "safer."
Of the currently available antiretroviral agents, QT liability has not been clearly and comparatively delineated for most drugs. With the exception of efavirenz, nonnucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors have not raised concerns of QT interval prolongation to date. Conversely, small signals of QT interval prolongation have been observed for some of the currently available protease inhibitors [5, 6] . Atazanavir did not demonstrate an effect on the corrected QT (QTc) interval or on QT dispersion in 1 study [6] , but it did impact the PR interval (which has been identified in other studies). However, signals of atazanavir's proclivity to delay ventricular repolarization were evident during clinical development [7] , and a recent report of its association with torsades de pointes exists (confirmed by rechallenge with subsequent QTc interval prolongation to 571 msec) [8] . The impact of some protease inhibitors on the human ether-a-go-go-related gene (hERG) blockade has been published, demonstrating that protease inhibitors possess some affinity toward the rapid component of the delayed rectifier potassium current, which mechanistically explains most cases of drug-induced torsades de pointes [5] .
Considering the fact that nonnucleoside reverse-transcriptase inhibitors and protease inhibitors are also cytochrome P450 (CYP) substrates and notorious inhibitors of CYP3A4 (table 1) , the additional risk of interactions with numerous drugs warrants significant attention. For example, concurrent administration of drugs that inhibit CYP3A4 activity (e.g., macrolides and azole antifungals) with efavirenz or protease inhibitors, which are CYP3A4 substrates with QT liability, may lead to increased exposure of the latter, to QT in-
